Open CFD account Free Demo
Call: +248 4 671 903 Mail: [email protected]
Log In Open Account
Log In Open Account
Log In Open Account
News & Analysis
Open Account
News & Analysis
Open Account

BioNTech tops Q4 expectations

28 March 2023 By Klavs Valters

Share

BioNTech SE (NASDAQ: BNTX) reported Q4 2022 financial results on Monday.

The German pharmaceutical company reported revenue of $4.563 billion for the quarter, topping analyst estimate of $3.897 billion.

Earnings per share (EPS) also beat analyst estimates at $9.876 per share vs. $8.296 EPS expected.

CEO commentary

”We made significant progress in 2022 by advancing our pipeline and launching the world’s first Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine. In addition, multiple new modalities achieved encouraging clinical data and we progressed nine new programs into clinical trials,” said professor Ugur Sahin, M.D., CEO and Co-Founder of BioNTech said in a press release.

”As we look to 2023 and beyond, we plan to continue investing in our transformation with a focus on building commercial capabilities in oncology and working towards registrational trials. Our mid-term goal is to seek approval for multiple oncology products in cancer indications with high unmet medical need,” he added.

The stock was down by -3.59% at market close on Tuesday at $123.19 per share.

Stock performance

  • 1 month: -5.55%
  • 3 months: -29.76%
  • Year-to-date: -17.72%
  • 1 year: -25.70%

BioNTech SE price targets

  • HC Wainwright & Co.: $210
  • JP Morgan: $142
  • Goldman Sachs: $156
  • Morgan Stanley: $216
  • B of A Securities: $239
  • SVB Leerink: $224
  • Canaccord Genuity: $192

BioNTech SE is the 576th largest company in the world with a market cap of $29.99 billion.

You can trade BioNTech SE (NASDAQ: BNTX) and many other stocks from the NYSE, NASDAQ, HKEX, ASX, LSE and DE with GO Markets as a Share CFD.

Sources: BioNTech SE, TradingView, MarketWatch, MetaTrader 5, Benzinga, CompaniesMarketCap

The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs. These documents are available here.